Wave Life Sciences Engages Investors with Upcoming Conferences
Wave Life Sciences Ltd. (Nasdaq: WVE), a cutting-edge biotechnology company, is gearing up to connect with investors at two important upcoming investor conferences. These events are a platform for Wave's management to share insights into their innovative work in RNA medicines, aimed to transform human health. This participation reflects the company’s commitment to transparency and engagement within the financial community.
Details of the Conferences
Guggenheim 2nd Annual Healthcare Innovation Conference
The first conference on the agenda is the Guggenheim 2nd Annual Healthcare Innovation Conference, scheduled for November 11. At this event, Paul Bolno, MD, MBA, President and CEO, will lead an analyst-led fireside chat at 10:00 AM ET. His discussion is anticipated to provide valuable insights into Wave’s strategies and recent advancements in the RNA therapeutics space.
Jefferies London Healthcare Conference
Following this, Wave is also set to participate in the Jefferies London Healthcare Conference on November 20. Dr. Bolno is expected to be involved in an analyst-led fireside chat at 8:30 AM GMT and will participate in the Anti-Obesity Panel at 9:00 AM GMT. This forum is particularly relevant as the discussion focuses on critical health issues, including obesity, where Wave has ongoing clinical programs.
Accessing the Webcasts
For those interested in following these discussions, live webcasts of the fireside chats will be available by visiting the Investor Events section on Wave Life Sciences’ website. This is an excellent opportunity for stakeholders to gain deeper insights into the company’s progress and future plans.
About Wave Life Sciences
Wave Life Sciences is pioneering the development of RNA medicines through its innovative PRISM platform. This technology combines a variety of methodologies and chemistry innovations to create effective therapies targeting both rare and common disorders. The company’s extensive pipeline includes exciting clinical programs addressing conditions such as obesity, alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, and Huntington’s disease, alongside several preclinical initiatives utilizing its RNA-targeting toolkit.
The company operates under the guiding principle of "Reimagine Possible," highlighting its commitment to enhancing human health by combating the limitations imposed by diseases. With headquarters in Cambridge, Massachusetts, Wave Life Sciences continues to make significant strides in the biotechnology field.
Contact Information
If you have any questions or require further information, reach out to Kate Rausch, VP of Corporate Affairs and Investor Relations at +1 617-949-4827. Investors can also connect with James Salierno, Director of Investor Relations, at +1 617-949-4043, or via email at InvestorRelations@wavelifesci.com.
For media inquiries, contact Katie Sullivan, Senior Director of Corporate Communications, at +1 617-949-2936 or email MediaRelations@wavelifesci.com.
Frequently Asked Questions
What is Wave Life Sciences?
Wave Life Sciences is a biotechnology company focused on developing RNA medicines to improve human health.
Where is Wave Life Sciences headquartered?
The company is headquartered in Cambridge, Massachusetts.
What conferences is Wave Life Sciences attending?
Wave Life Sciences is presenting at the Guggenheim 2nd Annual Healthcare Innovation Conference and the Jefferies London Healthcare Conference.
Who is leading the fireside chats?
Dr. Paul Bolno, President and CEO, will lead the discussions at both conferences.
How can I access the webcasts?
Live webcasts can be accessed via the Investor Events section on Wave Life Sciences' official website.